公开(公告)号：US06787534B2

公开(公告)日：2004-09-07

申请号：US10149253

申请日：2002-06-10

Applicant: Toru Haneda ,  Akihiko Tsuruoka ,  Junichi Kamata ,  Tadashi Okabe ,  Keiko Takahashi ,  Kazumasa Nara ,  Shinichi Hamaoka ,  Norihiro Ueda ,  Toshiaki Wakabayashi ,  Yasuhiro Funahashi ,  Taro Semba ,  Naoko Hata ,  Yuji Yamamoto ,  Yoichi Ozawa ,  Naoko Tsukahara ,  Takashi Owa

Inventor： Toru Haneda ,  Akihiko Tsuruoka ,  Junichi Kamata ,  Tadashi Okabe ,  Keiko Takahashi ,  Kazumasa Nara ,  Shinichi Hamaoka ,  Norihiro Ueda ,  Toshiaki Wakabayashi ,  Yasuhiro Funahashi ,  Taro Semba ,  Naoko Hata ,  Yuji Yamamoto ,  Yoichi Ozawa ,  Naoko Tsukahara ,  Takashi Owa

IPC: A61K3133

CPC classification number: C07D215/38 ,  C07D215/48 ,  C07D217/02 ,  C07D217/22 ,  C07D217/24 ,  C07D217/26 ,  C07D311/16 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D411/12 ,  C07D417/12 ,  C07D471/04

Abstract: The present invention provides a sulfonamide- or sulfonylurea-containing heterocyclic compounds. Specifically, it provides a heterocyclic compound represented by the formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, A is hydrogen atom, a halogen atom, a C1-C4 alkyl or alkoxy group which may be substituted with a halogen atom, or cyano group; B is an optionally substituted aryl group or monocyclic heteroaryl group, or: (wherein, the ring Q is an aromatic ring which may have nitrogen atom; and the ring M is a ring sharing a double bond with the ring Q, which ring may have a heteroatom; and the rings Q and M may share nitrogen atom); K is a single bond; T, W, X and Y are the same as or different from each other and each is ═C(D)— (wherein, D is hydrogen or a halogen atom) or nitrogen atom; U and V are the same as or different from each other and each is ═C(D)—, nitrogen atom, —CH2—, oxygen atom or —CO—; Z is a single bond or —CO—NH—; and R1 is hydrogen atom, etc.

Abstract translation: 本发明提供了含磺酰胺或磺酰脲的杂环化合物。 具体地说，它提供由式（I）表示的杂环化合物，其药理学上可接受的盐或它们的水合物。在该式中，A是氢原子，卤素原子，可以是C 1 -C 4烷基或烷氧基的 被卤素原子或氰基取代; B是任选取代的芳基或单环杂芳基，或者：（其中，环Q是可以具有氮原子的芳环;环M是与环Q共享双键的环，该环可以具有 杂原子;并且环Q和M可以共享氮原子）; K是单键; T，W，X和Y彼此相同或不同，并且各自为= C（D） - （其中，D为氢或卤素原子）或氮原子; U和V彼此相同或不同，并且各自为= C（D） - ，氮原子，-CH 2 - ，氧原子或-CO-; Z是单键或-CO-NH-; R1为氢原子等

公开(公告)号：US06469043B1

公开(公告)日：2002-10-22

申请号：US09647215

申请日：2000-09-28

Applicant: Toru Haneda ,  Akihiko Tsuruoka ,  Junichi Kamata ,  Tadashi Okabe ,  Keiko Takahashi ,  Kazumasa Nara ,  Shinichi Hamaoka ,  Norihiro Ueda ,  Takashi Owa ,  Toshiaki Wakabayashi ,  Yasuhiro Funahashi ,  Taro Semba ,  Naoko Hata ,  Yuji Yamamoto ,  Yoichi Ozawa ,  Noako Tsukahara

Inventor： Toru Haneda ,  Akihiko Tsuruoka ,  Junichi Kamata ,  Tadashi Okabe ,  Keiko Takahashi ,  Kazumasa Nara ,  Shinichi Hamaoka ,  Norihiro Ueda ,  Takashi Owa ,  Toshiaki Wakabayashi ,  Yasuhiro Funahashi ,  Taro Semba ,  Naoko Hata ,  Yuji Yamamoto ,  Yoichi Ozawa ,  Noako Tsukahara

IPC: A61K31404

CPC classification number: C07D401/12 ,  C07D209/04 ,  C07D209/30 ,  C07D209/42 ,  C07D403/12 ,  C07D409/12

Abstract: The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof. In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1˜C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1˜C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded. Further, when the ring A is cyanophenyl group, 2-amino-5-pyridyl group or a 2-halo-5-pyridyl group and R1 is cyano group or a halogen atom, at least one of R2 and R3 should not be a hydrogen atom.

Abstract translation: 本发明创造出一种新型抗血管生成剂，并提供与常规抗肿瘤剂相比显示出高安全性的抗肿瘤剂，具有确定的作用并且能够长时间施用。 也就是说，其提供由下式（I）表示的吲哚化合物，其药理学上可接受的盐或其水合物。在该式中，R1表示氢原子，卤素原子或氰基; R2和R3相同或不同，各自表示氢原子，C1〜C4低级烷基或卤原子; R4表示氢原子或C1〜C4低级烷基; 并且环A表示氰基苯基，氨基磺酰基苯基，氨基吡啶基，氨基嘧啶基，卤代吡啶基或氰基噻吩基，条件是所有的R 1，R 2和R 3均为氢原子，其中R 2和R 3均为氢原子或 环A为氨基磺酰基，R1和R2均为卤素原子。 此外，当环A为氰基苯基，2-氨基-5-吡啶基或2-卤代-5-吡啶基并且R 1为氰基或卤素原子时，R 2和R 3中的至少一个不应为氢 原子。

公开(公告)号：US06448243B1

公开(公告)日：2002-09-10

申请号：US09367227

申请日：1999-08-11

Applicant: Noritaka Kitazawa ,  Kohshi Ueno ,  Keiko Takahashi ,  Teiji Kimura ,  Atsushi Sasaki ,  Koki Kawano ,  Tadashi Okabe ,  Makoto Komatsu ,  Manabu Matsunaga ,  Atsuhiko Kubota

Inventor： Noritaka Kitazawa ,  Kohshi Ueno ,  Keiko Takahashi ,  Teiji Kimura ,  Atsushi Sasaki ,  Koki Kawano ,  Tadashi Okabe ,  Makoto Komatsu ,  Manabu Matsunaga ,  Atsuhiko Kubota

IPC: C07D40100

CPC classification number: C07D231/12 ,  C07D211/26 ,  C07D211/74 ,  C07D217/04 ,  C07D233/56 ,  C07D249/08 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D491/04 ,  C07D513/04

Abstract: A novel 1,4-substituted cyclic amine derivative represented by the following formula or a pharmacologically acceptable salt thereof: (wherein A, B, C, D, T, Y and Z represent each methine or nitrogen; R1, R2, R3, R4 and R5 represent each a substituent; n represents 0 or an integer of 1 to 3; m represents 0 or an integer of 1 to 6; and p represents an integer of 1 to 3.) The compound has a serotonin antagonism and is clinically useful as medicament, in particular, for treating, ameliorating and preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.

Abstract translation: 由下式表示的新的1,4-取代环胺衍生物或其药理学上可接受的盐：（其中A，B，C，D，T，Y和Z表示次甲基或氮; R1，R2，R3，R4 R5表示取代基，n表示0或1〜3的整数，m表示0或1〜6的整数，p表示1〜3的整数。）该化合物具有5-羟色胺拮抗作用，临床有用 作为药物，特别是用于治疗，改善和预防痉挛性麻痹或用于改善肌强直的中枢肌肉松弛剂。

公开(公告)号：US20130065925A1

公开(公告)日：2013-03-14

申请号：US13609716

申请日：2012-09-11

Applicant: Ichiro YOSHIDA ,  Tadashi OKABE ,  Yasunobu MATSUMOTO ,  Nobuhisa WATANABE ,  Yuji ONIZAWA ,  Yoshiaki OHASHI ,  Hitoshi HARADA

Inventor： Ichiro YOSHIDA ,  Tadashi OKABE ,  Yasunobu MATSUMOTO ,  Nobuhisa WATANABE ,  Yuji ONIZAWA ,  Yoshiaki OHASHI ,  Hitoshi HARADA

IPC: C07D401/12 ,  A61P1/04 ,  A61K31/4025 ,  A61P1/00 ,  A61K31/454 ,  C07D403/12

CPC classification number: A61K31/4025 ,  A61K31/454 ,  C07D401/12 ,  C07D403/12

Abstract: A compound represented by formula (1) or a pharmaceutically acceptable salt thereof has an inhibitory effect in the fractalkine-CX3CR1 pathway: wherein R represents a C1-6 alkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, a C3-8 cycloalkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, or a C3-8 cycloalkenyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, X represents a C1-6 alkyl group, Y and Z are the same or different from each other and each represents a halogen atom or a C1-6 alkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group B, n represents 0 or 1, Substituent Group A consists of halogen atoms, and Substituent Group B consists of halogen atoms.

Abstract translation: 由式（1）表示的化合物或其药学上可接受的盐具有抑制作用：其中R表示未取代的或具有1至3个选自取代基组A的取代基的C 1-6烷基，C3- 8个未取代的或具有1〜3个选自取代基组A的取代基的环烷基，或未取代或具有1-3个选自取代基组A的取代基的C 3-8环烯基，X表示C 1-6烷基，Y和Z是 相同或不同，各自表示卤素原子或未取代或具有1〜3个选自取代基组B的取代基的C 1-6烷基，n表示0或1，取代基组A由卤素原子和取代基组B 由卤素原子组成。

公开(公告)号：US07612114B2

公开(公告)日：2009-11-03

申请号：US11158245

申请日：2005-06-22

Applicant: Shinichi Hamaoka ,  Noritaka Kitazawa ,  Kazumasa Nara ,  Atsushi Sasaki ,  Atsushi Kamada ,  Tadashi Okabe

Inventor： Shinichi Hamaoka ,  Noritaka Kitazawa ,  Kazumasa Nara ,  Atsushi Sasaki ,  Atsushi Kamada ,  Tadashi Okabe

IPC: A61K31/136 ,  C07C211/44

CPC classification number: C07C217/22 ,  C07C215/78 ,  C07C217/18 ,  C07C217/78 ,  C07C217/84 ,  C07C219/34 ,  C07C323/25 ,  C07C2602/10 ,  C07D205/04 ,  C07D207/09 ,  C07D209/08 ,  C07D209/14 ,  C07D209/30 ,  C07D209/44 ,  C07D211/14 ,  C07D211/26 ,  C07D211/46 ,  C07D211/58 ,  C07D213/38 ,  C07D213/64 ,  C07D213/73 ,  C07D223/16 ,  C07D243/08 ,  C07D277/66 ,  C07D295/088 ,  C07D295/13 ,  C07D295/135 ,  C07D307/14 ,  C07D309/04 ,  C07D309/14 ,  C07D311/58 ,  C07D317/66 ,  C07D333/20 ,  C07D333/58 ,  C07D405/12 ,  C07D451/06 ,  C07D453/02 ,  C07D487/08 ,  C07D491/10 ,  C07F5/025 ,  C07F7/1804 ,  C07F7/2208

Abstract: The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R′ represents 1 to 4 independent hydrogen atoms and the like; and R″ represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.

Abstract translation: 本发明提供由下式（I）表示的化合物。 [其中T表示单键，可以具有取代基的C1-C4亚烷基等; “img id =”CUSTOM-CHARACTER-00001“he =”3.56mm“wi =”21.84mm“file =”US07612114-20091103-P00001.TIF“alt =”custom character“img-content =”character“img-format =“tif”/>式（I-1）表示单键或双键; A表示单键，可以具有取代基的二价5〜14元杂环基等; Y表示单键等; Z表示亚甲基等; 环G表示可以用5-至6-元环缩合并可具有杂原子的亚苯基等; R a和R b彼此相同或不同，表示氢原子等; W表示单键等; R'表示1〜4个独立的氢原子等; R“表示1〜4个独立的氢原子等]或其盐或其水合物。

公开(公告)号：US06875761B2

公开(公告)日：2005-04-05

申请号：US10796673

申请日：2004-03-10

Applicant: Kohshi Ueno ,  Atsushi Sasaki ,  Koki Kawano ,  Tadashi Okabe ,  Noritaka Kitazawa ,  Keiko Takahashi ,  Noboru Yamamoto ,  Yuichi Suzuki ,  Manabu Matsunaga ,  Atsuhiko Kubota

Inventor： Kohshi Ueno ,  Atsushi Sasaki ,  Koki Kawano ,  Tadashi Okabe ,  Noritaka Kitazawa ,  Keiko Takahashi ,  Noboru Yamamoto ,  Yuichi Suzuki ,  Manabu Matsunaga ,  Atsuhiko Kubota

IPC: C07D217/22 ,  C07D217/24 ,  C07D401/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D405/04 ,  C07D405/10 ,  C07D409/04 ,  C07D409/14 ,  C07D413/10 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04 ,  C07D491/04 ,  C07D491/10 ,  C07D495/04 ,  A61K31/33 ,  A61K31/47 ,  A61K31/495 ,  C07D217/00 ,  C07D241/04

CPC classification number: C07D401/04 ,  C07D217/22 ,  C07D217/24 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D405/04 ,  C07D405/10 ,  C07D409/04 ,  C07D409/14 ,  C07D413/10 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04 ,  C07D491/04 ,  C07D491/10 ,  C07D495/04

Abstract: Condensed pyridine compounds represented by formula (I): wherein: R1 and R3 are, independently, hydrogen, lower alkyl, or lower alkoxy; R2 represent an amino substituent; ring A is a benzene ring, pyridine ring, thiophene ring, or furan ring; and B represents a substituent containing a ring structure. Also, pharmaceutically acceptable salt and hydrates thereof. These compounds are clinically useful medicaments having serotonin antagonism, and in particular, for treating, ameliorating, or preventing spastic paralysis. They are also useful as central muscle relaxants for ameliorating myotonia.

Abstract translation: 由式（I）表示的缩合吡啶化合物：其中：R 1和R 3独立地是氢，低级烷基或低级烷氧基; R 2表示氨基取代基; 环A为苯环，吡啶环，噻吩环或呋喃环; B表示含有环结构的取代基。 此外，其药学上可接受的盐和水合物。 这些化合物是具有5-羟色胺拮抗作用的临床上有用的药物，特别是用于治疗，改善或预防痉挛性麻痹。 它们也可用作改善肌强直的中枢肌肉松弛剂。

公开(公告)号：US06638964B2

公开(公告)日：2003-10-28

申请号：US10098421

申请日：2002-03-18

Applicant: Toru Haneda ,  Akihiko Tsuruoka ,  Junichi Kamata ,  Tadashi Okabe ,  Keiko Takahashi ,  Kazumasa Nara ,  Shinichi Hamaoka ,  Norihiro Ueda ,  Takashi Owa ,  Toshiaki Wakabayashi ,  Yasuhiro Funahashi ,  Taro Semba ,  Naoko Hata ,  Yuji Yamamoto ,  Yoichi Ozawa ,  Noako Tsukahara

Inventor： Toru Haneda ,  Akihiko Tsuruoka ,  Junichi Kamata ,  Tadashi Okabe ,  Keiko Takahashi ,  Kazumasa Nara ,  Shinichi Hamaoka ,  Norihiro Ueda ,  Takashi Owa ,  Toshiaki Wakabayashi ,  Yasuhiro Funahashi ,  Taro Semba ,  Naoko Hata ,  Yuji Yamamoto ,  Yoichi Ozawa ,  Noako Tsukahara

IPC: A61K31405

CPC classification number: C07D401/12 ,  C07D209/04 ,  C07D209/30 ,  C07D209/42 ,  C07D403/12 ,  C07D409/12

Abstract: The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof: In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1˜C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1˜C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded. Further, when the ring A is cyanophenyl group, 2-amino-5-pyridyl group or a 2-halo-5-pyridyl group and R1 is cyano group or a halogen atom, at least one of R2 and R3 should not be a hydrogen atom.

Abstract translation: 本发明创造出一种新型抗血管生成剂，并提供与常规抗肿瘤剂相比显示出高安全性的抗肿瘤剂，具有确定的作用并且能够长时间施用。 也就是说，其提供由下式（I）表示的吲哚化合物，其药理学上可接受的盐或水合物：在式中，R 1表示氢原子，卤素原子或氰基; R 2和R 3各自代表氢原子，C 1 -C 4低级烷基或卤素原子; R 4表示氢原子或C 1 -C 4低级烷基; 并且环A表示氰基苯基，氨基磺酰基苯基，氨基吡啶基，氨基嘧啶基，卤代吡啶基或氰基噻吩基，条件是所有R 1，R 2和R 3均为氢原子的情况，其中 R 2和R 3都是氢原子，或者其中环A是氨基磺酰基并且R 1和R 2都是卤素原子。 此外，当环A为氰基苯基，2-氨基-5-吡啶基或2-卤代-5-吡啶基，R 1为氰基或卤素原子时，R 2和 R 3不应该是氢原子。

公开(公告)号：US06340759B1

公开(公告)日：2002-01-22

申请号：US09509778

申请日：2000-03-31

Applicant: Kohshi Ueno ,  Atsushi Sasaki ,  Koki Kawano ,  Tadashi Okabe ,  Noritaka Kitazawa ,  Keiko Takahashi ,  Noboru Yamamoto ,  Yuichi Suzuki ,  Manabu Matsunaga ,  Atsuhiko Kubota

Inventor： Kohshi Ueno ,  Atsushi Sasaki ,  Koki Kawano ,  Tadashi Okabe ,  Noritaka Kitazawa ,  Keiko Takahashi ,  Noboru Yamamoto ,  Yuichi Suzuki ,  Manabu Matsunaga ,  Atsuhiko Kubota

IPC: C07D24102

CPC classification number: C07D401/04 ,  C07D217/22 ,  C07D217/24 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D405/04 ,  C07D405/10 ,  C07D409/04 ,  C07D409/14 ,  C07D413/10 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04 ,  C07D491/04 ,  C07D491/10 ,  C07D495/04

Abstract: The present provides a condensed pyridine compound (I) represented by the following formula: (wherein, R2 represents ring A represents benzene ring, pyridine ring, thiophene ring or furan ring; and B represents its pharmaceutically acceptable salt or hydrates thereof, which is a clinically useful medicament having a serotonin antagonism, in particular, that for treating, ameliorating or preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.

Abstract translation: 本发明提供由下式表示的缩合吡啶化合物（I）（其中，R2表示A表示苯环，吡啶环，噻吩环或呋喃环; B表示其药学上可接受的盐或水合物，其为临床上有用的药物 具有5-羟色胺拮抗作用，特别是用于治疗，改善或预防痉挛性麻痹或用于改善肌强直的中枢肌肉松弛剂。

公开(公告)号：US20120004315A1

公开(公告)日：2012-01-05

申请号：US13048391

申请日：2011-03-15

Applicant: Shinichi Hamaoka ,  Noritaka Kitazawa ,  Kazumasa Nara ,  Atsushi Sasaki ,  Atsushi Kamada ,  Tadashi Okabe

Inventor： Shinichi Hamaoka ,  Noritaka Kitazawa ,  Kazumasa Nara ,  Atsushi Sasaki ,  Atsushi Kamada ,  Tadashi Okabe

IPC: A61K31/137 ,  A61P19/10 ,  A61P35/00 ,  C07C217/84

CPC classification number: C07C217/22 ,  C07C215/78 ,  C07C217/18 ,  C07C217/78 ,  C07C217/84 ,  C07C219/34 ,  C07C323/25 ,  C07C2602/10 ,  C07D205/04 ,  C07D207/09 ,  C07D209/08 ,  C07D209/14 ,  C07D209/30 ,  C07D209/44 ,  C07D211/14 ,  C07D211/26 ,  C07D211/46 ,  C07D211/58 ,  C07D213/38 ,  C07D213/64 ,  C07D213/73 ,  C07D223/16 ,  C07D243/08 ,  C07D277/66 ,  C07D295/088 ,  C07D295/13 ,  C07D295/135 ,  C07D307/14 ,  C07D309/04 ,  C07D309/14 ,  C07D311/58 ,  C07D317/66 ,  C07D333/20 ,  C07D333/58 ,  C07D405/12 ,  C07D451/06 ,  C07D453/02 ,  C07D487/08 ,  C07D491/10 ,  C07F5/025 ,  C07F7/1804 ,  C07F7/2208

Abstract: The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R′ represents 1 to 4 independent hydrogen atoms and the like; and R″ represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.

Abstract translation: 本发明提供由下式（I）表示的化合物。 [其中T表示单键，可以具有取代基的C1-C4亚烷基等; 式（I-1）表示单键或双键; A表示单键，可以具有取代基的二价5〜14元杂环基等; Y表示单键等; Z表示亚甲基等; 环G表示可以用5-至6-元环缩合并可具有杂原子的亚苯基等; R a和R b彼此相同或不同，表示氢原子等; W表示单键等; R'表示1〜4个独立的氢原子等; R“表示1〜4个独立的氢原子等]或其盐或其水合物。

公开(公告)号：US20090325930A1

公开(公告)日：2009-12-31

申请号：US12544965

申请日：2009-08-20

Applicant: Shinichi Hamaoka ,  Noritaka Kitazawa ,  Kazumasa Nara ,  Atsushi Sasaki ,  Atsushi Kamada ,  Tadashi Okabe

Inventor： Shinichi Hamaoka ,  Noritaka Kitazawa ,  Kazumasa Nara ,  Atsushi Sasaki ,  Atsushi Kamada ,  Tadashi Okabe

IPC: A61K31/55 ,  A61P25/00 ,  A61K31/445 ,  A61K31/454 ,  A61K31/138 ,  C07D401/12 ,  C07D223/04 ,  C07D417/12 ,  C07D211/06 ,  C07C211/44 ,  C07C217/64

CPC classification number: C07C217/22 ,  C07C215/78 ,  C07C217/18 ,  C07C217/78 ,  C07C217/84 ,  C07C219/34 ,  C07C323/25 ,  C07C2602/10 ,  C07D205/04 ,  C07D207/09 ,  C07D209/08 ,  C07D209/14 ,  C07D209/30 ,  C07D209/44 ,  C07D211/14 ,  C07D211/26 ,  C07D211/46 ,  C07D211/58 ,  C07D213/38 ,  C07D213/64 ,  C07D213/73 ,  C07D223/16 ,  C07D243/08 ,  C07D277/66 ,  C07D295/088 ,  C07D295/13 ,  C07D295/135 ,  C07D307/14 ,  C07D309/04 ,  C07D309/14 ,  C07D311/58 ,  C07D317/66 ,  C07D333/20 ,  C07D333/58 ,  C07D405/12 ,  C07D451/06 ,  C07D453/02 ,  C07D487/08 ,  C07D491/10 ,  C07F5/025 ,  C07F7/1804 ,  C07F7/2208

Abstract: The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like;   (I-1) formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R′ represents 1 to 4 independent hydrogen atoms and the like; and R″ represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.

Abstract translation: 本发明提供由下式（I）表示的化合物。 [其中T表示单键，可以具有取代基的C1-C4亚烷基等; “img id =”CUSTOM-CHARACTER-00001“he =”3.13mm“wi =”16.59mm“file =”US20090325930A1-20091231-P00001.TIF“img-content =”character“img-format =”tif“/> （I-1）式（I-1）表示单键或双键; A表示单键，可以具有取代基的二价5〜14元杂环基等; Y表示单键等; Z表示亚甲基等; 环G表示可以用5-至6-元环缩合并可具有杂原子的亚苯基等; R a和R b彼此相同或不同，表示氢原子等; W表示单键等; R'表示1〜4个独立的氢原子等; R“表示1〜4个独立的氢原子等]或其盐或其水合物。